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Abstract
 X . w X  Y .The aim of this study was to determine if the brain uptake of 4- 2 -methoxyphenyl -1- 2 - N-2 -pyridinyl -p-
w18 x x w18 x .F fluorobenzamido ethylpiperazine F MPPF , a radioligand for the imaging of 5-HT receptors, is influenced by the action of1A
P-glycoprotein.
w18 x  .Anesthetized male Wistar rats were injected i.v. with the 5-HT receptor antagonist F MPPF 2 MBq, S.A.)110 TBqrmmol1A
 .  X . w  . xafter treatment with saline controls or with the 5-HT receptor antagonist 1- 2 -methoxyphenyl -4- 4- 2-phtalimido butyl piperazine1A
 .  .NAN-190 2.5 mgrkg i.v. . After 60 min, the animals were sacrificed and 13 areas of the brain were dissected for ex vivo gamma
counting. The regional distribution of radioactivity was also assessed in brain slices using a storage phosphor system. Modulation of
 . w18 xP-glycoprotein was achieved by injection of cyclosporin A 50 mgrkg 30 min prior to injection of F MPPF.
The distribution of 18F-derived radioactivity corresponded to regional 5-HT receptor density as known from autoradiography.1A
w18 xModulation of P-glycoprotein with cyclosporin A caused a 5- to 10-fold increase in the uptake of F MPPF. Tissuercerebellum ratios in
the brain correlated with receptor densities determined by in vitro autoradiography. Measurements of plasma radioactivity showed that the
w18 x increased brain uptake of F MPPF is partially due to a rise in ligand delivery after treatment with cyclosporin A area under the curve,
.  .AUC, increased by a factor of 1.8 . Biodistribution experiments in wild type and mdr1a yry knockout mice confirmed that
w18 xF MPPF is a substrate for P-glycoprotein. q 2000 Elsevier Science B.V. All rights reserved.
 .Keywords: 5-HT receptor; Positron Emission Tomography PET ; P-glycoprotein1A
1. Introduction
 .Positron emission tomography PET and biodistribu-
tion studies in rats, cats, and monkeys have demonstrated
 X .that the regional distribution of 4- 2 -methoxyphenyl -1-
w X  Y . w18 x x2 - N-2 -pyridinyl - p - F fluorobenzamido ethylpipera-
w18 x .zine F MPPF in the brain corresponds to 5-HT1A
receptor localization Kung et al., 1996; Shiue et al., 1997;
.Le Bars et al., 1998; Ginovart et al., 2000 . Recently, our
w18 x group presented the first human data for F MPPF Pas-
.schier et al., 1999, 2000a,b . Again, the radioactivity distri-
bution in human CNS was in good agreement with known
receptor localization and with previous PET studies, which
w 11 x employed carbonyl- C WAY 100635 Farde et al., 1998;
.Gunn et al., 1998; Ito et al., 1999 . Shortly afterwards,
these results were confirmed by researchers from Liege`
 . w18 xPlenevaux et al., 1999 , indicating that F MPPF is a
) Corresponding author. Tel.: q31-50-361-3311; fax: q31-50-361-
1687.
 .E-mail address: aren@pet.azg.nl A. van Waarde .
useful radioligand for clinical application and may be
employed to measure the 5-HT receptor occupancy of1A
new drugs during phase 1 and 2 clinical trials.
w18 xComparison of data obtained for F MPPF in rats with
w 11 xdata for carbonyl- C WAY 100635, showed that MPPF
displays a six- to seven-fold lower uptake in the brain
 .data not shown . This difference must arise from the
p-fluoro-benzyl group in MPPF since the compounds are
 .otherwise identical Scheme 1 .
It is known that P-glycoprotein, an ATP-driven trans-
membrane efflux pump, which is present with high density
in brain endothelium, has a high affinity for lipophilic
molecules of moderate weight and size that contain cationic
centers and planar aromatic domains Abbott and Romero,
1996; Dellinger et al., 1992; Pawagi et al., 1994; Pearce et
al., 1990; Schinkel et al., 1996; Van Asperen et al., 1996,
.1997 . Active transport back into the blood could result in
w18 xa lower brain penetration of F MPPF than might be
expected from its lipophilicity. The efflux action of P-
glycoprotein can be inhibited by so-called modulators e.g.
. cyclosporin A, verapamil, and PSC833 Begley, 1992;
0014-2999r00r$ - see front matter q 2000 Elsevier Science B.V. All rights reserved.
 .PII: S0014-2999 00 00752-4
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Scheme 1. Characteristics of MPPF and WAY 100635.
Hendrikse et al., 1998; Hughes et al., 1998; Schinkel et al.,
.1995; Van Asperen et al., 1996 . These compounds reduce
P-glycoprotein functionality and thus prevent a radioligand
from being expelled from the endothelial membrane back
into the blood.
In rodents, two P-glycoproteins are present encoded by
the mdr1a and mdr1b genes. Brain P-glycoprotein is
expressed by the mdr1a gene Borst and Schinkel, 1996;
.Schinkel et al., 1995, 1996; Van Asperen et al., 1996 . The
generation of mice with homozygously disrupted mdr1a
w  . xgenes mdr1a yry knockout mice has made it possible
to test if the brain uptake of a drug is affected by the
action of P-glycoprotein Schinkel et al., 1995, 1996; Van
.Asperen et al., 1996 .
If uptake of the radiopharmaceutical in the brain is
indeed limited by the action of P-glycoprotein, inhibition
of this pump by a modulator could result in improved
counting statistics within the CNS. A positive result will
demonstrate the importance of taking the action of P-
glycoprotein into account during the development of radi-
oligands for CNS receptors and for 5-HT receptor antag-1A
onists in particular.
The aim of the present study was to investigate if the
introduction of the extra aromatic ring in MPPF results in
a decreased brain uptake due to the efflux action of
P-glycoprotein. To that purpose, biodistribution experi-
ments were performed in rats with modulated P-glyco-
 .protein functionality and in mdr1a yry knockout mice.
2. Materials and methods
All solvents were of analytical grade and were obtained
 . from Merck Darmstadt, Germany or Rathburn Walker-
.burn, Scotland . Chemicals were purchased from Aldrich
 .  .Milwaukee, USA and ACROS Chimica Geel, Belgium .
 .  .NAN-190 Hydrobromide and R - q -8-Hydroxy-DPAT
 .were from Sigma St. Louis, USA Cyclosporin A
 . Sandimmune was a product of Sandoz Basle, Switzer-
.  w .land . Ketamine Ketalar was purchased from Parke-
 .Davis Hoofddorp, The Netherlands and xylazine
 w .  .  XRompun from Bayer Leverkusen, Germany . 4- 2 -
. w X  Y . xmethoxyphenyl -1- 2 - N-2 -pyridinyl -p-nitrobenzamido -
 .  X . w Xethylpiperazine p-MPPNO , 4- 2 -methoxyphenyl -1- 2 -2
 Y . x N-2 -pyridinyl -p-fluorobenzamido ethylpiperazine p-
.    . xMPPF , and 2- 4- 2-methoxyphenyl -piperazin-1-yl -
4  .ethyl -piperidin-2-yl-amine WAY 100634 were prepared
according to a previously described method Zhuang et al.,
.1994 . C18 SepPak light and OASIS cartridges were ob-
tained from Waters Chromatography Division Milford,
.USA . Supelclean LC18 cartridges were produced by Su-
 .pelco Bellefonte, USA . High-performance liquid chro-
 .matography HPLC solvent was degassed and filtered
 .through 0.45 mm HA filters Millipore, Milford, USA .
Tissue radioactivity was determined with a calibrated
gamma counter LKB-Wallac Compugamma 1282 CS,
.Turku, Finland . Ex vivo storage phosphor imaging was
performed using a multi-purpose screen MP, Canberra-
.Packard Benelux, Groningen, The Netherlands . The ex-
posed screens were scanned with a Cyclonee storage
 .phosphor system Packard Biosciences, Meriden, USA .
( X ) [ Y )2.1. Synthesis of 4- 2 -methoxyphenyl -1- 2 -pyridinyl -p-
[18 ] ] [18 ]F fluorobenzamido ethyl-piperazine, F MPPF
w18 xNo carrier added F MPPF was synthesized according
to a literature procedure with several adjustments Le Bars
. w18 x  .et al., 1998 . Aqueous F fluoride 1 ml was prepared by
18  .18the O p,n F nuclear reaction in a 0.8-ml silver target.
The enriched water was recovered by elution over an
 . w18 xAG1-X8 ion exchange column K CO -form . F Fluo-2 3
 .ride was eluted with a solution of K CO 5 mg in water2 3
 . w x.1 ml into a vial containing Kryptofix 2.2.2. Kr222
 . w xq18 y12–13 mg . The resulting Kr222 F complex was
dried by four successive azeotropical evaporations with
 .  Xacetonitrile 1=1 ml, 3=0.5 ml . The precursor, 4- 2 -
. w X  Y . xmethoxyphenyl -1- 2 - N-2 - pyridinyl - p-nitrobenzamido
 .  .ethylpiperazine 7 mg in DMF 0.7 ml , was added and
the reaction mixture was heated to 1408C for 25 min. The
 .reaction was quenched with water 4 ml and the mixture
was passed through a Supelclean LC18 cartridge. The
 .cartridge was washed with water 2 ml , 18% EtOH in
 .  .water 4 ml and eluted with a mixture of methanol 1 ml
 .and THF 0.33 ml , into a vial containing 1-ml water.
Next, the solution was filtered 0.45 mm, Millex, non-
. sterile and purified by HPLC Phenomenex: Ultracarb
ODS 30: 250=10 mm; MeOHrTHFrNaOAc 0.01 M,
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. .pHs7.3 , 41:14:45; 3.0 mlrmin . The fraction containing
w18 x F MPPF t s30–35 min, U.V. 254 nm, S.A.)110R
.TBqrmmol was collected, and the product was formu-
lated according to a modified literature procedure Lemaire
. w18 xet al., 1995 . The fraction containing F MPPF was
diluted in 100-ml distilled water. Methanol and THF were
removed by passing the mixture over a C18 SepPak light
cartridge, followed by rinsing of the cartridge with 2=8
w18 xml of 0.9% saline solution. F MPPF was eluted and
formulated by passing 0.8 ml ethanol through the car-
 .tridge, followed by 8 ml phosphate buffer pHs7.4–7.6 .
After filtration through a 0.22-mm sterile filter Millex,
.GP , the product was ready for injection. Quality control
using reverse phase HPLC WATERS NovaPak: 150=3.6
 .mm, ACNrTHFrNaOAc 0.01 M, pHs5 , 28:6:65; 1.5
 .  . .mlrmin: t MPPF s 5 min, t MPPNO s 7 minR R 2
showed a radiochemical purity )99%. The amounts of
WAY 100634 and MPPNO were <1 mgrl. The radio-2
 .chemical yield was 7% end of bombardment . Total syn-
thesis time was 120 min.
( )2.1.1. Octanolrwater partition coefficient logP
w18 x1.85–3.7 MBq of F MPPF was dissolved in 0.1 M
 . phosphate buffer pH 7.4 5 ml , whereafter n-octanol 5
.ml was added. The mixture was vigorously shaken at
378C for 30 min. One hundred microliters of the n-octanol
layer and of the water layer were counted in a calibrated
gamma counter. The partition coefficient was calculated
 .using: log Ps log counts in octanolrcounts in water .
2.2. Distribution studies in rat brain
2.2.1. Biodistribution
All experiments were carried out in compliance with the
Law on Animal Experimentation of the Netherlands. Male
 . Wistar rats 229"22 g supplied by Harlan Lelystad, The
.Netherlands were anesthetized by intraperitoneal injection
 .of sodium pentobarbital 60 mgrkg . Two minutes before
w18 x administration of F MPPF 2 MBq, S.A.) 110
. TBqrmmol , the rats were treated either with saline con-
.trol group or with the 5-HT receptor antagonist NAN-1A
 .190 2.5 mgrkg by i.v. injection into the tail vein. One
hour after injection of the radioligand, the animals were
sacrificed and 13 areas of the brain were dissected.
The time course of the experiment is illustrated in
Scheme 2. Tissue radioactivity was measured with a cali-
brated gamma counter. The samples were weighed and
tissue uptake was expressed as standard uptake value
 .  . suv : cpm measuredrg tissue r cpm injectedrg body
.weight . Residual uptake in the presence of NAN-190 was
considered to represent nonspecific binding Glennon et
.al., 1988; Rydelek-Fitzgerald et al., 1990 . To modulate
P-glycoprotein function in control and 5-HT blocked1A
 .animals, cyclosporin A 50 mgrkg was injected into the
penile vein 30 min prior to radioligand administration
 .Scheme 2 .
2.2.2. Dissection of brain regions
The entorhinal cortex and the piriform cortex containing
the amygdaloid nucleus were removed on the ventral side
of the brain. Olfactory bulbs were dissected and the brain
was cut in three coronal slices. The first coronal cut was
 .made "2 mm caudal to the olfactory bulbs A3000 mm ,
 .the second just caudal to the optic chiasm P1500 mm
 .Doze et al., 1998; Palkovits and Brownstein, 1988 . From
the first slice, anterior cingulaterfrontopolar cortex was
dissected. The second slice was used to isolate striatum
and frontal cortex. Thalami could be scooped out from the
third brain slice. In the same slice, the remainder of the
cortex was peeled off, containing parietal, temporal and
occipital areas, after which the hippocampi could be re-
moved as well. Then, the cerebellar hemispheres were
removed from the hindbrain and the pons and medulla
were obtained by sectioning through the pons just caudal
to the occipital cortex. Right and left samples of all brain
regions were pooled.
2.2.3. Phosphor screen imaging
Male Wistar rats were either treated with saline con-
.trols , the selective 5-HT receptor antagonist NAN-190,1A
or the selective 5-HT agonist 8-OH-DPAT, 2 min before1A
w18 xinjection of 10–15 MBq of F MPPF into the tail vein.
After 60 min, the animals were sacrificed. Brains were
removed from the skull, frozen on dry ice, and cut into
w18 xScheme 2. Experimental time course of F MPPF distribution studies in rats. P s time of pentobarbital administration in case of cyclosporin ACsA
pretreatment, P s time of pentobarbital administration in experiments without cyclosporin A pretreatment, SrNssaline or NAN-190, Rs radioligand,con
Ts termination followed by dissection of tissues.
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w18 x  .  . )Fig. 1. Central uptake of F MPPF 60 min p.i. . Specific binding was defined by residual uptake after predosing with NAN-190 2.5 mgrkg . Indicates
 .significant difference Student’s t-test, P-0.05 . CER—cerebellum, THA—thalamus, STR—striatum, MED—medulla, OLF—olfactory bulbs,
PTOC—parietal-rtemporal-roccipital cortex, FC—frontal cortex, CC—cingulate cortex, APC—amygdala-rpiriform cortex, EC—entorhinal cortex, HIP
—hippocampus.
 .slices of 80 mm by means of a microtome y6 to y108C .
Bregma levels: 2.70, 2.20, 1.60–1.20, 0.20, y1.30, y1.80,
y2.30ry2.80, y3.60ry3.80, y4.52, y5.20ry5.30,
y5.60ry5.80, y6.04ry6.30 Paxinos and Watson,
.1998 . Three slices were taken from the cerebellumr
medulla. All slices were covered with a multi-purpose
 .storage phosphor screen. After 20–24 h )10 half-lives
of exposure, the screens were scanned using a storage
phosphor system.
[18 ]2.2.4. Plasma clearance of F MPPF
One of the carotid arteries of anesthetized male Wistar
 .rats either untreated or treated with Cyclosporin A was
cannulated. After radioligand administration, blood sam-
 .ples 150 ml were drawn at different time intervals over a
period of 60 min. After centrifugation Hettich mikroliter;
.3 min at 15.000 rpm , plasma radioactivity was measured
with a calibrated gamma counter. The samples were
weighed and plasma uptake was expressed as standard
 .uptake value. The area under the curve AUC was calcu-
lated by nonlinear curve fitting.
( )2.3. Cerebral distribution in wild type and mdr1a yry
knockout mice
Male wild type 27.4"2 g, ns5; Harlan, The Nether-
.  . lands or mdr1a yry FVB mice 31.3"2 g, ns3;
kindly provided by The Netherlands Cancer Institute in
.Amsterdam between 9 and 16 weeks of age were anes-
 .  .Fig. 2. Ex vivo autoradiography of rat brain at different levels using phosphor storage imaging. Top images A represent control slices, bottom images B
 .represent the corresponding slices after pretreatment with NAN-190 2.5 kgrmg . I—Septal area, II—Dentate gyrus, IIIrIV—Hippocampus.
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w18 xFig. 3. Comparison of the tissuercerebellum ratios of F MPPF ob-
tained from ex vivo autoradiography with regional 5-HT receptor1A
w 3 xdensities determined by in vitro autoradiography with methoxy- H WAY
 .  .  .100635 Khawaja, 1995 . B —Caudate Nucleus, \ —Frontal cortex,
v .  .  .
—Septo hippocampal area, e —Cingulate cortex, m —Amygdala
 .  .hippocampal area, ^ —Lateral septum ventral, [ —Hippocampus
 .  .  .CA1, I —Dentate gyrus, l —Lateral septum dorsal, ‘ —Lateral
 .septum intermediate, ’ —Hippocampus CA3.
thetized by intraperitoneal injection of ketaminerxylazine
 w w .Ketalar rRompun ; 2:1, 1 mlrkg . One hour after i.v.
w18 xadministration of F MPPF into the tail vein, the animals
were sacrificed and several tissues were dissected accord-
ing to the procedure mentioned above. Tissue uptake of
radioactivity was expressed as standard uptake value.
3. Results
[18 ]3.1. F MPPF uptake and distribution in rat brain
 .We measured a log P of 2.14"0.06 ns5 for
w18 xF MPPF. On the basis of this value, a good uptake of
the radioligand in the brain could be expected. However,
measured uptake values in biodistribution experiments were
w18 xquite low. The uptake of F MPPF in the brain of saline-
and NAN-190 pretreated Wistar rats is presented in Fig. 1.
Standard uptake values were in the range of 0.05–0.25. A
 .significant reduction caused by NAN-190 2.5 mgrkg
was observed in hippocampus, amygdalarpiriform-, cingu-
laterfrontopolar-, and entorhinal cortex Student’s t-test,
.ns6: P-0.05 .
Because of the low standard uptake values, ex vivo
phosphor storage imaging experiments were performed to
w18 xconfirm the in vivo selectivity of F MPPF for the 5-HT1A
receptor in rat brain. The results for saline- and NAN-190
pretreated rats are displayed in Fig. 2. Uptake was highest
 .in septal and hippocampal areas Fig. 2A; ns3 . After
 .treatment with NAN-190 2.5 mgrkg; ns3 , specific
 .binding was no longer observed Fig. 2B .
w18 xTissuercerebellum ratios for F MPPF in the phos-
phor storage imaging experiments were excellently cor-
related with receptor densities measured by in vitro
wautoradiography in the same animal species using metho-
3 x  .  .xxy- H WAY 100635 Fig. 3 Khawaja, 1995 .
w18 x  .  .Fig. 4. Central uptake of F MPPF 60 min p.i. after pretreatment with cyclosporin A 50 mgrkg 30 min prior to injection of the radioligand. Specific
binding and regions are defined as in Fig. 1.
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w18 x  .Fig. 5. Comparison of the tissuercerebellum ratios of F MPPF in vivo after modulation with cyclosporin A 50 mgrkg with regional 5-HT receptor1A
 .  .  .  .  .  .densities determined by ex vivo autoradiography Hume et al., 1994 . 1 —Striatum, 2 —Thalamus, 3 —Medulla, 4 —Olfactory bulbs, 5 —Frontal
 .  .  .  .cortex, 6 —Amygdalarpiriform cortex, 7 —Cingulaterfrontopolar cortex, 8 —Entorhinal cortex, 9 —Hippocampus.
3.2. Influence of P-glycoprotein modulation on central
[18 ]uptake and distribution of F MPPF in rats
After modulation of P-glycoprotein functionality by
pretreatment of animals with cyclosporin A 50 mgrkg, 30
w18 x .min prior to administration of F MPPF , tissue uptake
was increased in all brain regions Fig. 4, compare Fig. 4
.with Fig. 1; P-0.05 . A significant reduction of tissue
 .radioactivity by NAN-190 2.5 mgrkg could be seen in
hippocampus, amygdalarpiriform-, cingulaterfrontopolar-,
 . )  .Fig. 6. Difference in cerebral uptake between FVB wild and mdr1a yry knockout mice. Indicates significant difference Student’s t-test, P-0.05 .
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entorhinal cortex and also in the frontal- and in the pari-
 .etal-rtemporal-rocccipital cortex Fig. 4 .
w18 xIn Fig. 5, tissuercerebellum ratios of F MPPF in
cyclosporin A-treated animals are compared to receptor
density values obtained from biodistribution studies with
w 3 x  .methoxy- H WAY 100635 Hume et al., 1994 . A good
correlation is observed and the regression line intercepts
the Y-axis at approximately Ys1 a receptor density of
.zero corresponds to a tissuercerebellum ratio of 1 .
Because the levels of radioactivity in plasma were
increased after 60 min in the cyclosporin A-treated ani-
mals, the effect of cyclosporin A on ligand delivery to the
brain was determined. The clearance rate of injected ra-
dioactivity was determined by analyzing the AUC for
control and cyclosporin A-treated animals. A significant
decrease in the clearance of MPPF-derived radioactivity
was observed after treatment with cyclosporin A, leading
to a 1.84"0.37-fold increase of the AUC ns5 for
.control, ns5 for cyclosporin A-treated animals .
[18 ]3.3. Comparison between brain uptake of F MPPF in
( )FVB wild-type and mdr1a yry knockout mice
w18 xTo confirm that the increased uptake of F MPPF in
rat brain after pretreatment with cyclosporin A is due to
modulation of P-glycoprotein functionality, biodistribution
 .  .was compared in FVB-wild ns5 and mdr1a yry
 . w18 xknockout mice ns3 . Uptake of F MPPF in the brain
 .of mdr1a yry knockout mice was two- to three-fold
 .higher than in the wild type Fig. 6 .
4. Discussion
Biodistribution experiments showed a five- to seven-fold
lower brain uptake for the 5-HT receptor antagonist1A
MPPF compared to the prototype ligand WAY 100635
 . Fig. 1A Plenevaux et al., 1997; Shiue et al., 1997; Pike
.et al., 1994 . This was unexpected since the lipophilicity of
MPPF is sufficient for rapid diffusion through the blood–
 .brain barrier log Ps2.14 . Since biodistribution is a rather
crude method that does not provide information on ligand
 .uptake in small greater than a few millimeter areas, ex
vivo autoradiography was performed using a phosphor
 .storage system Fig. 2 . A laminar distribution of radioac-
tivity was observed, which corresponds to 5-HT receptor1A
 .distribution in rat brain Fig. 2A . Tissuercerebellum ra-
tios obtained from these images closely correlated with
known receptor densities as determined by in vitro auto-
 .  .radiography Fig. 3 Khawaja, 1995 . Pretreatment with
NAN-190, a selective 5-HT partial receptor antagonist1A
 . Glennon et al., 1988 and with 8-OH DPAT data not
. shown , a selective 5-HT receptor agonist Arvidsson et1A
.al., 1981; Rydelek-Fitzgerald et al., 1990 , reduced the
w18 xuptake of F MPPF to the same values as were observed
 . w18 xfor cerebellum Fig. 2B , confirming that F MPPF binds
selectively to 5-HT receptors in rat brain in vivo.1A
To determine the cause of the reduced cerebral uptake
of MPPF as compared to WAY 100635, we decided to test
if the former is a substrate for P-glycoprotein. After treat-
w18 xment with cyclosporin A, brain uptake of F MPPF was
 .increased four- to six-fold Figs. 1 and 4 . Whereas in
control rats, no significant specific binding could be ob-
served in the frontal-, parietal-, temporal-, and occipital
 .cortices in the biodistribution experiments Fig. 1 , modu-
lation of P-glycoprotein functionality with cyclosporin A
led to a significant difference between control and NAN-
 .190-pretreated animals in these regions Fig. 4 , while
tissuercerebellum ratios remained in good agreement with
w 3 xreceptor densities as determined with methoxy- H WAY
 .  .100635 Fig. 5 Hume et al., 1994 . It is clear that in
some brain areas, P-glycoprotein modulation results in
increased radioligand uptake and, therefore, improved
counting statistics.
w18 xThe increase of F MPPF derived radioactivity in the
brain after administration of cyclosporin A was partially
due to increased ligand delivery to the brain AUC in
.plasma: cyclosporin Arcontrols1.84 . To prove that
w18 xF MPPF is a substrate for P-glycoprotein and that the
observed differences in cerebral uptake between cy-
closporin A-treated and control animals were not solely
due to altered pharmacokinetics, we compared the cerebral
 .uptake in wild type and mdr1a yry knockout mice. A
 .significant increase two- to three-fold was found in the
 .knockout mice Fig. 6 . These results lead us to conclude
that the extra aromatic ring in MPPF causes an increased
efflux action exerted by P-glycoprotein, and a lower brain
uptake than would be predicted from its lipophilicity. The
excellent results obtained with volunteers and with ex vivo
storage phosphor imaging of rat brain show that the inter-
action with P-glycoprotein is not associated with a dimin-
w18 xished selectivity of F MPPF for the 5-HT receptor1A
 .Passchier et al., 2000a,b , but it does stress the importance
of taking the presence of P-glycoprotein into account
during the development of radioligands for CNS receptors
and for 5-HT receptor antagonists in particular.1A
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